DelveInsight’s, “Lymphatic Malformations Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Lymphatic Malformations Pipeline landscape. It covers the Lymphatic Malformations pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lymphatic Malformations pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Lymphatic Malformations Pipeline Report

• DelveInsight’s Lymphatic Malformations pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Lymphatic Malformations treatment.
• The leading companies working in the Lymphatic Malformations Market include Protara therapeutics, Vanthera, Cerecor Inc., and others.
• Promising Lymphatic Malformations Pipeline Therapies in the various stages of development include TARA-002, PTX-022, ZYN002, NB-001, and others.
• November 2023: Protara Therapeutics announced a study of Phase 2 clinical trials for TARA-002. This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.
• November 2023: Zynerba Pharmaceuticals Inc. announced a study of Phase 1 & 2 clinical trials for ZYN002. To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in patients ages 4 to < 18 years, in the treatment of 22q.11.2 Deletion Syndrome (22qDS). This is an open-label study to assess the safety, tolerability and efficacy of cannabidiol (CBD) administered as ZYN002, a transdermal gel, for the treatment of child and adolescent patients with 22qDS. Male and female patients with 22qDS will be treated in Period 1 for 14 weeks. Patients that meet study criteria will be allowed to continue to Period 2 for an additional 24 weeks of treatment. At the end of study, patients taking antiepileptic drug (AED) medication(s) will have an additional one or two week Taper Period. Approximately 20 male and female patients, ages 4 to < 18 years, will receive ZYN002.
• October 2023: Nobias Therapeutics Inc. announced a study of Phase 2 clinical trials for NB-001. This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric conditions. The trial is designed to allow all visits to be conducted via telephone and/or video (i.e., telemedicine) or by home health nurse. An in-person visit is required at Screening unless site or government mandates restrict this due to coronavirus disease-2019 (COVID-19).

 

Request a sample and discover the recent advances in Lymphatic Malformations Treatment Drugs @ Lymphatic Malformations Pipeline Report

 

In the Lymphatic Malformations Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lymphatic Malformations collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Lymphatic Malformations Overview

Lymphatic malformations are rare, non-malignant masses consisting of fluid-filled channels or spaces thought to be caused by the abnormal development of the lymphatic system. In lymphatic malformations, movement of lymphatic fluid into veins is slow or decreased. This causes extra fluid to collect and to enlarge the lymphatic channels.

 

Find out more about Lymphatic Malformations Therapeutics Assessment @ Lymphatic Malformations Preclinical and Discovery Stage Products

 

Lymphatic Malformations Emerging Drugs Profile

• TARA-002: Protara Therapeutics
• VT30: Vanthera

 

Lymphatic Malformations Pipeline Therapeutics Assessment

There are approx. 4+ key companies which are developing the Lymphatic Malformations therapies. The Lymphatic Malformations companies which have their Lymphatic Malformations drug candidates in the most advanced stage, i.e. phase II include, Protara Therapeutics.

 

DelveInsight’s Lymphatic Malformations Pipeline report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Lymphatic Malformations pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Lymphatic Malformations Pipeline Products have been categorized under various Molecule types such as

• Peptides
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Lymphatic Malformations Pipeline Therapies @ Lymphatic Malformations Clinical Trials Assessment

 

Scope of the Lymphatic Malformations Pipeline Report

• Coverage- Global
• Lymphatic Malformations Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Lymphatic Malformations Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Lymphatic Malformations Companies- Protara therapeutics, Vanthera, Cerecor Inc., and others.
• Lymphatic Malformations Pipeline Therapies- TARA-002, PTX-022, ZYN002, NB-001, and others.

 

Dive deep into rich insights for new drugs for Lymphatic Malformations Treatment, Visit @ Lymphatic Malformations Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Lymphatic Malformations: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Lymphatic Malformations– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Lymphatic Malformations Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TARA-002: Protara Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. VT30: Vanthera
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Lymphatic Malformations Key Companies
20. Lymphatic Malformations Key Products
21. Lymphatic Malformations- Unmet Needs
22. Lymphatic Malformations- Market Drivers and Barriers
23. Lymphatic Malformations- Future Perspectives and Conclusion
24. Lymphatic Malformations Analyst Views
25. Lymphatic Malformations Key Companies
26. Appendix

 

For further information on the Lymphatic Malformations Pipeline therapeutics, reach out to Lymphatic Malformations Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lymphatic-malformations-market